Abstract
Integrins are a large family of transmembrane heterodimeric proteins that constitute the main receptors for extracellular matrix components. Integrins were initially thought to be primarily involved in the maintenance of cell adhesion and tissue integrity. However, it is now appreciated that integrins play important roles in many other biological processes such as cell survival, proliferation, differentiation, migration, cell shape and polarity. Lung cells express numerous combinations and permutations of integrin heterodimers. The complexity and diversity of different integrin heterodimers being implicated in different lung diseases present a major challenge for drug development. Here we provide a comprehensive overview of the current knowledge of integrins from studies in cell culture to integrin knockout mouse models and provide an update of results from clinical trials for which integrins are therapeutic targets with a focus on respiratory diseases (asthma, emphysema, pneumonia, lung cancer, pulmonary fibrosis and sarcoidosis).
Keywords: Asthma, emphysema, integrins, lung cancer, lung disease, pulmonary fibrosis, sarcoidosis.
Current Molecular Medicine
Title:Integrins as Therapeutic Targets for Respiratory Diseases
Volume: 15 Issue: 8
Author(s): C. M. Teoh, S. S.L. Tan and T. Tran
Affiliation:
Keywords: Asthma, emphysema, integrins, lung cancer, lung disease, pulmonary fibrosis, sarcoidosis.
Abstract: Integrins are a large family of transmembrane heterodimeric proteins that constitute the main receptors for extracellular matrix components. Integrins were initially thought to be primarily involved in the maintenance of cell adhesion and tissue integrity. However, it is now appreciated that integrins play important roles in many other biological processes such as cell survival, proliferation, differentiation, migration, cell shape and polarity. Lung cells express numerous combinations and permutations of integrin heterodimers. The complexity and diversity of different integrin heterodimers being implicated in different lung diseases present a major challenge for drug development. Here we provide a comprehensive overview of the current knowledge of integrins from studies in cell culture to integrin knockout mouse models and provide an update of results from clinical trials for which integrins are therapeutic targets with a focus on respiratory diseases (asthma, emphysema, pneumonia, lung cancer, pulmonary fibrosis and sarcoidosis).
Export Options
About this article
Cite this article as:
Teoh M. C., Tan S.L. S. and Tran T., Integrins as Therapeutic Targets for Respiratory Diseases, Current Molecular Medicine 2015; 15 (8) . https://dx.doi.org/10.2174/1566524015666150921105339
DOI https://dx.doi.org/10.2174/1566524015666150921105339 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structure of Cytochrome P450s and Personalized Drug
Current Medicinal Chemistry Multi-targeting Andrographolide and its Natural Analogs as Potential Therapeutic Agents
Current Topics in Medicinal Chemistry Estrogen Regulation of MicroRNA Expression
Current Genomics Cytotoxic Nitrobenzoyloxy-substituted Sesquiterpenes from Spongederived Endozoic Fungus Aspergillus insulicola MD10-2
Current Pharmaceutical Biotechnology Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Lung Cancer: Are we up to the Challenge?
Current Genomics Stem Cell Based Preclinical Drug Development and Toxicity Prediction
Current Pharmaceutical Design Comparison of Efficacy and Peripheral Neuropathy of Solvent-based Paclitaxel with Paclitaxel Poliglumex and NK105: A Systematic Review and Metaanalysis
Current Pharmaceutical Design Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology
Recent Patents on Anti-Cancer Drug Discovery Novel Therapeutic Approaches Targeting Vascular Endothelial Growth Factor and its Receptors in Haematological Malignancies
Current Cancer Drug Targets Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions
Current Drug Metabolism Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism Molecular and Genetic Bases of Pancreatic Cancer
Current Drug Targets Nanosuspensions of Poorly Water Soluble Drugs Prepared by Top-down Technologies
Current Pharmaceutical Design Molecular Remodeling of the Insulin Receptor Pathway by Thiazolidinediones in Type 2 Diabetes Mellitus: A Brief Review
Protein & Peptide Letters Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical Nanotechnology The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer
Current Clinical Pharmacology A Sialic Acid-Specific Lectin from the Mushroom Paecilomyces Japonica that Exhibits Hemagglutination Activity and Cytotoxicity
Protein & Peptide Letters